Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Editas Medicine, Inc.

Get SEC filing alerts via email and in your feed for Editas Medicine, Inc.

EDIT

Editas Medicine, Inc.

About Editas Medicine, Inc.

Editas Medicine, Inc. is a pioneering biotech company specializing in CRISPR-based gene editing to develop transformative genomic medicines. Its core focus is on in vivo editing therapies for serious diseases like sickle cell disease and beta-thalassemia, targeting hematopoietic stem cells, liver, and other tissues. The company leverages proprietary CRISPR platforms, advanced delivery technologies, and strategic licensing to create durable, scalable treatments for previously untreatable conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Editas Medicine, Inc.

1
1
Editas Medicine, Inc. Editas Medicine Reports $24.98 Million Net Loss in Q1 2026, Focuses on Gene Editing Candidate

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Editas Medicine, Inc. Editas Medicine Reports $160.1 Million Net Loss for 2025, Revenue Increases to $40.5 Million

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Editas Medicine, Inc. Editas Medicine Reports Revenue Growth and Decreased Operating Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Editas Medicine, Inc. Editas Medicine Reports Q2 2025 Financial Results with Reduced Net Loss and Increased R&D Revenues

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Editas Medicine, Inc. Editas Medicine Reports $76.1 Million Net Loss and Revenue Growth in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Editas Medicine, Inc. Editas Medicine Reports $237.1 Million Net Loss for 2024, Revenue Declines to $32.3 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Editas Medicine, Inc. Editas Medicine Reports Financial Results for Q3 2024, Net Loss Increases to $62.1 Million

Via official filing (AI summary) | over 1 year ago | 0 comments